2/25
10:24 am
beam
Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.
Medium
Report
Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.
2/25
08:42 am
beam
Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.
Medium
Report
Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.
2/25
07:22 am
beam
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/24
10:56 am
beam
Beam Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Beam Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
07:01 am
beam
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Medium
Report
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
2/24
07:00 am
beam
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
High
Report
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
2/23
07:05 pm
beam
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program [Yahoo! Finance]
High
Report
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program [Yahoo! Finance]
2/23
04:00 pm
beam
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
High
Report
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
2/21
06:31 am
beam
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.
2/20
08:02 am
beam
Beam Therapeutics (NASDAQ:BEAM) was given a new $74.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Beam Therapeutics (NASDAQ:BEAM) was given a new $74.00 price target on by analysts at Canaccord Genuity Group Inc..
2/18
07:46 pm
beam
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory [Yahoo! Finance]
Low
Report
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory [Yahoo! Finance]
2/15
07:12 pm
beam
Why Beam Therapeutics (BEAM) Is Up 5.3% After New Gene-Editing IP Deal And FDA Fast Track [Yahoo! Finance]
Low
Report
Why Beam Therapeutics (BEAM) Is Up 5.3% After New Gene-Editing IP Deal And FDA Fast Track [Yahoo! Finance]
2/15
08:53 am
beam
H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval [Yahoo! Finance]
Low
Report
H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval [Yahoo! Finance]
2/8
02:04 am
beam
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at
Wall Stree
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at
Wall Stree
1/29
07:31 am
beam
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) [Yahoo! Finance]
Low
Report
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) [Yahoo! Finance]
1/22
03:21 pm
beam
Cathie Wood quietly buys $7.27 million of popular tech stock [Yahoo! Finance]
Low
Report
Cathie Wood quietly buys $7.27 million of popular tech stock [Yahoo! Finance]
1/21
10:57 am
beam
Beam Therapeutics (NASDAQ:BEAM) was given a new $41.00 price target on by analysts at Tudor Pickering.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) was given a new $41.00 price target on by analysts at Tudor Pickering.
1/20
07:09 pm
beam
Beam Therapeutics (NASDAQ:BEAM) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
1/13
03:17 pm
beam
Beam Therapeutics: Pivoting From Platform To Execution Stage [Seeking Alpha]
Low
Report
Beam Therapeutics: Pivoting From Platform To Execution Stage [Seeking Alpha]
1/13
06:36 am
beam
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]
Medium
Report
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]
1/12
12:51 pm
beam
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]
Low
Report
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]
1/11
05:13 pm
beam
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]
High
Report
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]
1/11
05:00 pm
beam
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
High
Report
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
1/11
01:03 am
beam
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at
Wall Stree
High
Report
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at
Wall Stree
1/9
06:10 am
beam
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.